GUMDROP : UMD - A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100

Created by Nancy Dawson, last modified on Jun 25, 2013
Description:This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.
Link:http://clinicaltrials.gov/ct2/show/NCT01605227
Site:University of Maryland
Principal Investigator:Arif Hussain, MD